Table 1.
Characteristics of the patient cohort.
| Overall | Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis | Large vessel vasculitis | |
|---|---|---|---|
| n (%) | 117 (100) | 97 (82.9) | 20 (17.1) |
| Granulomatosis with polyangiitis (GPA) | 69 (71.1) | ||
| Eosinophilic granulomatosis with polyangiitis (EGPA) | 16 (16.5) | ||
| Microscopic polyangiitis (MPA) | 12 (12.4) | ||
| Giant cell arteritis (GCA) | 17 (85.0) | ||
| Takayasu's arteritis | 3 (15.0) | ||
| Age; mean (SD) | 56.3 (15.6) | 55.5 (15.4) | 60.0 (16.3) |
| Sex; n (%) | |||
| Female | 73 (62.4) | 56 (57.7) | 17 (85.0) |
| Male | 43 (36.8) | 40 (41.2) | 3 (15.0) |
| Non-binary | 1 (0.9) | 1 (1.0) | 0 (0.0) |
| Body mass index; kg/m2 mean (SD) | 26.3 (5.4) | 26.6 (5.6) | 24.9 (4.2) |
| Immunosuppressive therapy; n (%) | |||
| Rituximab Infusion (past six months) | 38 (32.5) | 38 (39.2) | 0 (0.0) |
| Cyclophosphamide | 7 (6.0) | 6 (6.2) | 1 (5.0) |
| Tocilizumab | 6 (5.1) | 0 (0.0) | 6 (30.0) |
| Mepolizumab | 4 (3.4) | 4 (4.1) | 0 (0.0) |
| Azathioprine | 16 (13.7) | 16 (16.5) | 0 (0.0) |
| Methotrexate | 25 (21.4) | 21 (21.6) | 4 (20.0) |
| Aprelimast | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Prednisolone; n (%) | |||
| >7.5 mg/day | 11 (9.5) | 8 (8.3) | 3.0 (15.0) |
| ≥5 and ≤ 7.5 mg/day | 35 (30.2) | 31 (32.3) | 4.0 (20.0) |
| < 5 mg/day | 33 (28.4) | 25 (26.0) | 8.0 (40.0) |
| Inhaled corticosteroids (alone or in combination) | 4 (3.4) | 4 (4.2) | 0.0 (0.0) |
| Other | 10 (8.6) | 6 (8.3) | 1 (10.0) |
| Main provider of vasculitis care; n (%) | |||
| General practitioner | 7 (6.5) | 2 (2.2) | 5 (26.3) |
| Nephrologist | 13 (12.0) | 13 (14.6) | 0 (0.0) |
| Rheumatologist | 87 (80.6) | 73 (82.0) | 14 (73.7) |
| Main provider of other medical issues; n (%) | |||
| Dermatologist | 1 (0.9) | 1 (1.1) | 0 (0.0) |
| General practitioner | 77 (71.3) | 63 (70.8) | 14 (73.7) |
| Nephrologist | 5 (4.6) | 5 (5.6) | 0 (0.0) |
| Neurologist | 1 (0.9) | 0 (0.0) | 1 (5.3) |
| Rheumatologist | 10 (9.3) | 7 (7.0) | 3 (15.8) |
| Other | 14 (13.0) | 13 (14.6) | 1 (5.3) |
| Current status; n (%) | |||
| Disease in remission | 76 (76.0) | 66 (79.5) | 10 (58.8) |
| Active disease | 24 (24.0) | 17 (20.5) | 7 (41.2) |
| Disease progression; n (%) | |||
| Relapsing | 43 (44.3) | 35 (43.2) | 8 (50.0) |
| Persistently active | 10 (10.3) | 7 (8.6) | 3 (18.8) |
| In remission after initial therapy | 44 (45.4) | 39 (48.1) | 5 (31.2) |
| Overall health status; n (%) | |||
| Excellent | 1 (1.0) | 1 (1.1) | 0 (0.0) |
| Very good | 12 (11.4) | 10 (11.5) | 2 (11.1) |
| Good | 43 (41.0) | 36 (41.4) | 7 (38.9) |
| Less good | 39 (37.1) | 30 (34.5) | 9 (50.0) |
| Poor | 10 (9.5) | 10 (11.5) | 0 (0.0) |
Values shown are means ± SD or medians followed by the IQR, as indicated. The bold values indicate the numbers of the overall study population.